Thanks for your adds here. A few weeks ago I posted about the Delta 32 deletion differences between non-European, or Bubonic plaque affected populations versus others. I wasn’t aware of single allele versus double allele deletions. Thx for that lesson. And your post today, shines some extra light on the difference in populations, not only generally, but in regards to the patients in our Nash study at 350mg and 700mg. So thx again.

Here’s a link to a company PR right after the trial publication in Dummer 2022.

Christopher P. Recknor, M.D., CytoDyn’s Senior Executive Vice President of Clinical Operations, stated, “We thank our sites, vendors and staff who helped make this trial possible. We are in the process of analyzing biomarker data including CCR5 haplotype information to better understand responder rates and mechanism of action. Given 5% of the world population is estimated to have NASH with 20% progressing to cirrhosis, this signal gives hope for a therapeutic intervention for this disease.”

My guess is Cytodyn is aware of exactly what you pointed out today. However, with Recknor ascent, perhaps a reminder would help.

“https://www.biospace.com/article/releases/leronlimab-14-week-nash-clinical-trial-met-primary-endpoint-pdff-and-secondary-endpoint-ct1-for-per-protocol-population-in-350-mg-weekly-dose/”